Decipher by Veracyte
Decipher by Veracyte
  • Видео 36
  • Просмотров 69 118
Decipher Prostate GRID Overview (RUO)
In this video, Dr. Ashley Ross, a Urologic Oncologist and Associate Professor of Urology at Northwestern Medicine, provides a page-by-page overview of the Decipher Prostate GRID Report. Veracyte provides curated Decipher GRID gene expression and signature data upon request on a RESEARCH USE ONLY basis.
Page 1 - 2:18
Page 2 - 7:47
Page 3 - 15:51
Page 4 - 17:52
Page 5 - 19:16
Page 6 - 21:18
Page 7 - 21:45
Просмотров: 1 608

Видео

Decipher Test Report Overview
Просмотров 6 тыс.10 месяцев назад
In this video, Dr. Ashley Ross, a Urologic Oncologist and Associate Professor of Urology at Northwestern Medicine, provides a page-by-page overview of the Decipher Prostate Biopsy and Radical Prostatectomy Reports. Introduction - 0:00 Page 1 - Overview - 0:30 Page 1 - Decipher Genomic Score Interpretation - 1:27 Page 1 - Risk Estimates - 4:03 Page 2 - Risk Comparison Graphic - 6:47 Page 2 - Tre...
Decipher Prostate Genomic Classifier by Veracyte - A different approach to prostate cancer
Просмотров 1,5 тыс.2 года назад
Have you or a loved one recently been diagnosed with prostate cancer? Learn more about how Veracyte's Decipher Prostate GenDeomic Classifier can help you and your doctor make the right treatment decisions for your unique case of prostate cancer.
Decipher Prostate Biopsy Report by Veracyte
Просмотров 4,9 тыс.2 года назад
The Decipher Prostate Biopsy report makes it easier to understand and discuss your patient's personalized genomic test results.
Decipher Prostate RP Next-Generation Report
Просмотров 2,9 тыс.3 года назад
Men diagnosed with prostate cancer who undergo radical prostatectomy may require additional treatment depending on several clinical factors, and in particular, the dynamics of their PSA. The underlying biology unique to every prostate cancer tumor determines whether it will progress or metastasize. Taking into account the entire biology of tumors, Decipher Prostate was specifically developed to...
Matthew Cooperberg, MD, MPH on Biomarkers in Prostate Cancer Active Surveillance
Просмотров 3,1 тыс.3 года назад
Matthew Cooperberg, MD, MPH from the University of California San Francisco presents his perspective on the use of biomarkers in the prostate cancer active surveillance. Following the presentation, Robert Den, MD from Thomas Jefferson University, and Sanoj Punnen, MD, join Dr. Cooperberg in a follow-up question and answer session.
Role of Decipher in Managing High Risk Localized Prostate Cancer
Просмотров 2,6 тыс.4 года назад
A Decipher Biosciences webinar featuring Dr. Paul Nguyen of Harvard Medical School.
Decipher Prostate Case Review: Impact of Genomics in Decision Making for Intermediate Risk Disease
Просмотров 2,2 тыс.4 года назад
A Decipher Biosciences webinar featuring Dr. Ashley Ross of Northwestern University and Dr. Phuoc Tran of Johns Hopkins University.
A Genomic Guide to Inform Multidisciplinary Management of Post-RP Radiation Therapy
Просмотров 6964 года назад
Webinar with Dr. Edouard Trabulsi, MD and Dr. Robert Den, MD from Thomas Jefferson University
Intermediate Risk Prostate Cancer: Felix Feng, MD
Просмотров 2,9 тыс.4 года назад
Felix Feng, MD, Professor of Radiation Oncology, Urology and Medicine at University of California, San Francisco discusses the intermediate risk prostate cancer stratification challenge and the utility of genomics in this setting
Molecular subtyping in prostate cancer: Felix Feng, MD
Просмотров 1624 года назад
Felix Feng, MD, Professor of Radiation Oncology, Urology and Medicine at University of California, San Francisco discusses genomic subtyping in prostate cancer and how it is being investigated in prospective trials
Case Study #3: Applying a Clinical Genomic Nomogram to the ADT Decision in 46 y.o. w/ Gleason 4+3=7
Просмотров 3,8 тыс.4 года назад
Jeff M. Michalski, MD, MBA, FASTRO provides an overview of the novel decision making approach he’s developed as an extension of the clinical-genomic nomogram developed by Spratt et al. (JCO 2018). Dr. Michalski presents a case study of a 46 year-old man with Gleason 4 3=7 prostate cancer demonstrating how he uses the nomogram to help address the dilemma surrounding ADT-related decisions in newl...
Case Study #2: Applying a Clinical Genomic Nomogram to the ADT Decision in 67 y.o. w/ Gleason 4+3=7
Просмотров 4,6 тыс.4 года назад
Jeff M. Michalski, MD, MBA, FASTRO provides an overview of the novel decision making approach he’s developed as an extension of the clinical-genomic nomogram developed by Spratt et al. (JCO 2018). Dr. Michalski presents a case study of a 67 year-old man with Gleason 4 3=7 prostate cancer demonstrating how he uses the nomogram to help address the dilemma surrounding ADT-related decisions in newl...
Case Study #1: Applying a Clinical Genomic Nomogram to the ADT Decision in High Volume Gleason 3+4=7
Просмотров 1,4 тыс.4 года назад
Jeff M. Michalski, MD, MBA, FASTRO provides an overview of the novel decision making approach he’s developed as an extension of the clinical-genomic nomogram developed by Spratt et al. (JCO 2018). Dr. Michalski presents a case study of a man with high volume, Gleason 3 4=7 prostate cancer demonstrating how he uses the nomogram to help address the dilemma surrounding ADT-related decisions in new...
Case Study #4: Applying a Clinical Genomic Nomogram to the ADT Decision in Low Volume Gleason 3+4=7
Просмотров 2,9 тыс.4 года назад
Jeff M. Michalski, MD, MBA, FASTRO provides an overview of the novel decision making approach he’s developed as an extension of the clinical-genomic nomogram developed by Spratt et al. (JCO 2018). Dr. Michalski presents a case study of a man with low volume, Gleason 3 4=7 prostate cancer demonstrating how he uses the nomogram to help address the dilemma surrounding ADT-related decisions in newl...
Applying a Clinical Genomic Nomogram for ADT Decisions in Intermediate Risk Prostate Cancer
Просмотров 7464 года назад
Applying a Clinical Genomic Nomogram for ADT Decisions in Intermediate Risk Prostate Cancer
Decipher Prostate: A Different Approach to Prostate Cancer ... We're Here to Help
Просмотров 4,3 тыс.4 года назад
Decipher Prostate: A Different Approach to Prostate Cancer ... We're Here to Help
Using Decipher Testing to Inform ADT Decisions in Intermediate Risk Prostate Cancer
Просмотров 1,4 тыс.4 года назад
Using Decipher Testing to Inform ADT Decisions in Intermediate Risk Prostate Cancer
Decipher in CHAARTED: Dr. Anis Hamid, MBBS
Просмотров 1384 года назад
Decipher in CHAARTED: Dr. Anis Hamid, MBBS
Metastatic hormone sensitive prostate cancer: Dr. Anis Hamid, MBBS
Просмотров 954 года назад
Metastatic hormone sensitive prostate cancer: Dr. Anis Hamid, MBBS
The role of genomics in newly diagnosed prostate cancer: Ashley Ross, MD, PhD
Просмотров 1,8 тыс.4 года назад
The role of genomics in newly diagnosed prostate cancer: Ashley Ross, MD, PhD
Men with high risk features post-RP: Ashley Ross, MD, PhD
Просмотров 9034 года назад
Men with high risk features post-RP: Ashley Ross, MD, PhD
Decipher Can Help Prioritize Patient Follow Up
Просмотров 1024 года назад
Decipher Can Help Prioritize Patient Follow Up
The smoldering PSA: Judd W. Moul, MD
Просмотров 2 тыс.4 года назад
The smoldering PSA: Judd W. Moul, MD
Radiation timing in the post-RP setting: Judd W. Moul, MD
Просмотров 3374 года назад
Radiation timing in the post-RP setting: Judd W. Moul, MD
Intermediate Risk Prostate Cancer: Paul Nguyen, MD
Просмотров 5 тыс.4 года назад
Intermediate Risk Prostate Cancer: Paul Nguyen, MD
The treatment paradigm for prostate cancer patients with biochemical recurrence: Paul Nguyen, MD
Просмотров 1,5 тыс.4 года назад
The treatment paradigm for prostate cancer patients with biochemical recurrence: Paul Nguyen, MD
Intermediate Risk Prostate Cancer: Daniel Spratt, MD
Просмотров 5 тыс.4 года назад
Intermediate Risk Prostate Cancer: Daniel Spratt, MD
RAVES and RADICALS: Daniel Spratt, MD
Просмотров 3944 года назад
RAVES and RADICALS: Daniel Spratt, MD
Decipher in the Post Radical Prostatectomy Setting: Ilia Zeltser, MD
Просмотров 6204 года назад
Decipher in the Post Radical Prostatectomy Setting: Ilia Zeltser, MD

Комментарии

  • @greetingsearthlingspluto6666
    @greetingsearthlingspluto6666 2 месяца назад

    This confused me.

  • @anthonykrzywicki8099
    @anthonykrzywicki8099 3 месяца назад

    Look under the hood of Decipher…. Especially the data base upon which their conclusions are formed. Also understand what the statistics really mean and the data used.

  • @anthonykrzywicki8099
    @anthonykrzywicki8099 4 месяца назад

    Proof of your approach please…. How successful was your protocol. Thank you. It’s been 2 years.

  • @spitfirekid1
    @spitfirekid1 8 месяцев назад

    Great surgeon and a terrific human being.

  • @jeffmorgan5152
    @jeffmorgan5152 10 месяцев назад

    With men starving for information it is difficult to understand how this does not have significantly more views. I could easily be one of these borderline UFIR patient case studies, and had to win a bit of a food fight with my urologist to get Decipher testing done at all. (Eventually accomplished with assistance from rad oncologist.) 61yrs, PSA 12.4, 3+4 in 6 of 12, 33cc, T2a, pi-rads 5....Decipher in the high intermediate range has made SBRT + 4 mos orgovyx a much easier pill to swallow. PROSTOX low was a bonus. Thank you gentlemen.

  • @jimh3595
    @jimh3595 Год назад

    I'm there right now. Gleason 3+4 and favorable intermediate. RO told me if decipher comes back negative that I'll need treatment. Also getting genetic testing.

  • @charlesblumenstock9160
    @charlesblumenstock9160 Год назад

    I agree bio markers are usefull in active surveilance

  • @charlesblumenstock9160
    @charlesblumenstock9160 Год назад

    I agree there are intermediate prostate risks the free psa is the one people talk about what is the cutoff point

  • @charlesblumenstock9160
    @charlesblumenstock9160 Год назад

    It's amazing all the new urine tests most require a prostate dre to get a good first catch approach different scores for all it's better then a bioppsie which is the gold standard

  • @heinhtetnaing3389
    @heinhtetnaing3389 Год назад

    Handsome and smart doctor. But this channel has little marketing sense.

  • @julitoyranela7928
    @julitoyranela7928 Год назад

    thank you Doc I am blessed to be your patient

  • @MM-sf3rl
    @MM-sf3rl Год назад

    Wow, what an honest discussion. In my prostate experience, this has not happened. Good on the Doc’s. Thanks for sharing your hard earned learning.

  • @daisuke6072
    @daisuke6072 2 года назад

    PSMA Pet scan?

  • @gaitanaminniti2023
    @gaitanaminniti2023 2 года назад

    traducir al CASTELLANO

  • @BKKKevin
    @BKKKevin 2 года назад

    Has anyone quantified the increased relapse risk on not adding ADT vs the increased risk of ADT side effects (Weight gain, muscle bone loss and heart issues)?… Couldn’t ADT be put off and used in a second round if relapse it detected with early PSA and PSMA Pet scans?

    • @davewilton3101
      @davewilton3101 8 месяцев назад

      I have one 3+4 and three 3+3 as per a recent fusion mri targeted biopsy. PSA 7.12. I was recently offered radiation and ADT however i did not wish the adt side effects, chose radiation only, and my radiation oncologist concurred as we can start ADT if needed in the future. I am 71 this spring. Had the RO insisted it was needed my response would have been when do we start. Quality of life was a big part of my thought process. I'm still in decent shape and enjoy some physical activities. While the loss of sexual activity is still important it rated down the scale of concerns. While i will always have second thoughts re ADT in life all we can do sometimes is make the best decision with the info we have and grab the dice and roll them.

  • @fatfrreddy1414
    @fatfrreddy1414 2 года назад

    speak English for us civilians..

  • @daviddyke1782
    @daviddyke1782 3 года назад

    This is a very important video more families should see it. I was diagnosed with Prostate Cancer and decided after exploring different options on having a Radical Robotic Prostatectomy. ........I made a short film of my journey from Diagnosis to Rehabilitation - its on RUclips this link will take you there.:- ruclips.net/video/PutQPR1-ExA/видео.html

  • @alanblack5665
    @alanblack5665 3 года назад

    Interesting but not sure where it takes us in relation to recurrence. Can a PSMA PET scan differentiate between benign and cancerous prostate tissue after surgery? I just had a PSMA scan initial feedback prior to consultation in a few weeks is that cancer has not spread despite a rising PSA. If it is identified in PSMA scan as benign, then this would radically influence any treatment plan

  • @paulsdrc
    @paulsdrc 3 года назад

    This is cool, I wish they would have had it when I started my prostate adventure. I was a Gleason 6, and told I was very early. But I went from one mass to two in 6 months, so another biopsy. And the doctors shook their head and said “you don’t have small cell carcinoma”, that shouldn’t happen. I just said I didn’t care how, lets fix it, I had HIFU and now cancer free for 6 years.

    • @kennytraylor6798
      @kennytraylor6798 3 года назад

      That’s great. I bet you had to pay out of pocket for HIFU ? Hope your still cancer free. ?

    • @paulsdrc
      @paulsdrc 3 года назад

      @@kennytraylor6798 yes I did, but now you can get it done here, and they say its covered. Cancer free 5 years now

  • @IanGracias342134
    @IanGracias342134 4 года назад

    I'm currently on that boarder line.... Now waiting results of biopsy

    • @fatfrreddy1414
      @fatfrreddy1414 2 года назад

      what you eat and drink is important, I've found...or what you DON'T eat n drink!

    • @RH-xd3nx
      @RH-xd3nx 2 года назад

      @@fatfrreddy1414 can you elaborate please?

  • @watchmine5531
    @watchmine5531 4 года назад

    There might be fake ones out there but real one do exist contact @Darknills on *telegram* he is the real vendor, I got my cc with high balance from him yesterday 🙏